JP7809060B2 - ペプチド化合物およびそれを用いる疾患の治療方法 - Google Patents

ペプチド化合物およびそれを用いる疾患の治療方法

Info

Publication number
JP7809060B2
JP7809060B2 JP2022542986A JP2022542986A JP7809060B2 JP 7809060 B2 JP7809060 B2 JP 7809060B2 JP 2022542986 A JP2022542986 A JP 2022542986A JP 2022542986 A JP2022542986 A JP 2022542986A JP 7809060 B2 JP7809060 B2 JP 7809060B2
Authority
JP
Japan
Prior art keywords
peptide
seq
peptides
present
synthetic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510019A (ja
JP2023510019A5 (enExample
Inventor
エラン オヴァディア
アヴィ ベン－シモン
イラナ コーヘン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunity Pharma Ltd
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of JP2023510019A publication Critical patent/JP2023510019A/ja
Publication of JP2023510019A5 publication Critical patent/JP2023510019A5/ja
Application granted granted Critical
Publication of JP7809060B2 publication Critical patent/JP7809060B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2022542986A 2020-01-15 2021-01-14 ペプチド化合物およびそれを用いる疾患の治療方法 Active JP7809060B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL272074A IL272074B2 (en) 2020-01-15 2020-01-15 Peptide compounds and methods of treating diseases using same
IL272074 2020-01-15
PCT/IL2021/050044 WO2021144798A1 (en) 2020-01-15 2021-01-14 Peptide compounds and methods of treating diseases using same

Publications (3)

Publication Number Publication Date
JP2023510019A JP2023510019A (ja) 2023-03-10
JP2023510019A5 JP2023510019A5 (enExample) 2024-01-19
JP7809060B2 true JP7809060B2 (ja) 2026-01-30

Family

ID=76863930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542986A Active JP7809060B2 (ja) 2020-01-15 2021-01-14 ペプチド化合物およびそれを用いる疾患の治療方法

Country Status (12)

Country Link
US (1) US20230049549A1 (enExample)
EP (1) EP4090347A1 (enExample)
JP (1) JP7809060B2 (enExample)
KR (1) KR20220145826A (enExample)
CN (6) CN119708144A (enExample)
AU (1) AU2021207415A1 (enExample)
BR (1) BR112022013978A2 (enExample)
CA (1) CA3167139A1 (enExample)
CO (1) CO2022011101A2 (enExample)
IL (1) IL272074B2 (enExample)
MX (1) MX2022008746A (enExample)
WO (1) WO2021144798A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280101B2 (en) 2018-07-11 2025-05-01 Immunity Pharma Ltd Peptide compounds and their therapeutic uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510796A (ja) 2004-08-23 2008-04-10 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
WO2012160563A2 (en) 2011-05-23 2012-11-29 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
WO2003037172A2 (en) * 2001-11-01 2003-05-08 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
US8648045B2 (en) * 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
CA2737924A1 (en) * 2008-10-06 2010-04-15 Joshua Robert Schultz Methods of treating inflammation
US20130096070A1 (en) * 2009-04-07 2013-04-18 University Of Kansas Peptide targeting of inner ear cells
BR112017022845A2 (pt) * 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
IL280101B2 (en) * 2018-07-11 2025-05-01 Immunity Pharma Ltd Peptide compounds and their therapeutic uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510796A (ja) 2004-08-23 2008-04-10 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
WO2012160563A2 (en) 2011-05-23 2012-11-29 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same

Also Published As

Publication number Publication date
MX2022008746A (es) 2022-10-13
WO2021144798A1 (en) 2021-07-22
CN119708141A (zh) 2025-03-28
CN115942948A (zh) 2023-04-07
CA3167139A1 (en) 2021-07-22
EP4090347A1 (en) 2022-11-23
US20230049549A1 (en) 2023-02-16
CN119708142A (zh) 2025-03-28
CO2022011101A2 (es) 2022-11-08
AU2021207415A1 (en) 2022-09-08
CN119708144A (zh) 2025-03-28
JP2023510019A (ja) 2023-03-10
IL272074B2 (en) 2024-12-01
CN119708143A (zh) 2025-03-28
IL272074A (en) 2021-07-29
CN115942948B (zh) 2025-01-14
BR112022013978A2 (pt) 2022-10-11
CN119708140A (zh) 2025-03-28
KR20220145826A (ko) 2022-10-31
IL272074B1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US20100081611A1 (en) Stabilized maml peptides and uses thereof
JP7682248B2 (ja) ペプチド化合物およびその治療的用途
JP7809060B2 (ja) ペプチド化合物およびそれを用いる疾患の治療方法
EP2578226B1 (en) Peptide for treating amyotrophic lateral sclerosis
RU2812775C2 (ru) Пептидные соединения и их терапевтическое применение
RU2843553C2 (ru) Пептидные соединения и их терапевтическое применение
EA044784B1 (ru) Пептидные соединения и способы лечения заболеваний с их использованием
EA051325B1 (ru) Пептидные соединения и их терапевтическое применение
EA046208B1 (ru) Пептидные соединения и их терапевтическое применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260120

R150 Certificate of patent or registration of utility model

Ref document number: 7809060

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150